E S Kropacheva

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Topics

Atrial Fibrillation

Top Venues

Terapevticheskii arkhiv

This page only lists publications with an associated author ORCID identifier.

Publications

E N Krivosheeva, A L Komarov, E P Panchenko, M B Khakimova, E S Kropacheva, Olga A Pogorelova, Tatyana V Balakhonova, E V Titaeva, A B Dobrovolsky, D M Galyautdinov, E E Vlasova
[GDF-15 and the risk of bleeding in patients with stable CAD receiving multicomponent antithrombotic therapy: the results of the prospective REGATA register]. Terapevticheskii arkhiv 96 (7) (2024)
E S Kropacheva, O A Zemlyanskaya, E N Krivosheeva, E P Panchenko
[Resumption of anticoagulant therapy after major bleeding and the risk of negative events in patients with atrial fibrillation (based on REGistry of Long-term AnTithrombotic TherApy-2 - REGATA)]. Terapevticheskii arkhiv 94 (12) (2023)
E S Kropacheva, O A Zemlyanskaya, E N Krivosheeva, E P Panchenko
[Resumption of anticoagulant therapy after major bleeding and the risk of negative events in patients with atrial fibrillation (based on REGistry of Long-term AnTithrombotic TherApy-2 - REGATA)]. Terapevticheskii arkhiv 94 (12) (2023)
E S Kropacheva, O A Zemlyanskaya, E N Krivosheeva, E P Panchenko
[Resumption of anticoagulant therapy after major bleeding and the risk of negative events in patients with atrial fibrillation (based on REGistry of Long-term AnTithrombotic TherApy-2 - REGATA)]. Terapevticheskii arkhiv 94 (12) (2023)
E S Kropacheva, M B Khakimova, E N Krivosheeva, O A Zemlyanskaya, E P Panchenko
[Severe gastrointestinal bleeding in patients with atrial fibrillation receiving oral anticoagulants (based on REGistry of long-term AnTithrombotic TherApy - REGATTA)]. Terapevticheskii arkhiv 93 (9) (2021)
A I Mironova Staroverova, E P Panchenko, E S Kropacheva, O A Zemlyanskaya
[Resumption of anticoagulant therapy after major bleeding and recurrence of hemorrhagic complications in patients with atrial fibrillation with a high risk of stroke and thromboembolism (based on the results of 20 years of observation)]. Terapevticheskii arkhiv 92 (9) (2020)